Search

5 result(s) for 'author#Kristina Striepe' within BMC

1. A randomised study of the impact of the SGLT2 inhibitor dapagliflozin on microvascular and macrovascular circulation

   The sodium–glucose cotransporter 2 inhibitor, dapagliflozin, has been shown to improve diabetic control and reduce blood pressure in patients with type 2 diabetes mellitus. Its effects on micro- and macrovascu...

   Authors: Christian Ott, Agnes Jumar, Kristina Striepe, Stefanie Friedrich, Marina V. Karg, Peter Bramlage and Roland E. Schmieder

   Citation: Cardiovascular Diabetology 2017 16:26

   Content type: Original article Published on: 23 February 2017

   • View Full Text
   • View PDF

2. How does empagliflozin improve arterial stiffness in patients with type 2 diabetes mellitus? Sub analysis of a clinical trial

   Empagliflozin has been shown to reduce cardiovascular mortality, but the underlying pathogenetic mechanisms are poorly understood. It was previously demonstrated that empagliflozin improved arterial stiffness.

   Authors: Agnes Bosch, Christian Ott, Susanne Jung, Kristina Striepe, Marina V. Karg, Dennis Kannenkeril, Thomas Dienemann and Roland E. Schmieder

   Citation: Cardiovascular Diabetology 2019 18:44

   Content type: Original investigation Published on: 29 March 2019

   • View Full Text
   • View PDF

3. Change of renal function after short-term use of cardioprotective agents in patients with type 2 diabetes is not accurately assessed by the change of estimated glomerular filtration rate: an observational study

   After initiating cardioprotective agents, a fall of estimated glomerular filtration rate (eGFR) has been reported in several studies. Our goal was to evaluate the accuracy of change of Chronic Kidney Disease E...

   Authors: Julie Kolwelter, Kristina Striepe, Agnes Bosch, Dennis Kannenkeril, Christian Ott, Mario Schiffer and Roland E. Schmieder

   Citation: Diabetology & Metabolic Syndrome 2022 14:102

   Content type: Research Published on: 21 July 2022

   • View Full Text
   • View PDF

4. Renal hemodynamic effects differ between antidiabetic combination strategies: randomized controlled clinical trial comparing empagliflozin/linagliptin with metformin/insulin glargine

   Type 2 diabetes causes cardio-renal complications and is treated with different combination therapies. The renal hemodynamics profile of such combination therapies has not been evaluated in detail.

   Authors: Christian Ott, Susanne Jung, Manuel Korn, Dennis Kannenkeril, Agnes Bosch, Julie Kolwelter, Kristina Striepe, Peter Bramlage, Mario Schiffer and Roland E. Schmieder

   Citation: Cardiovascular Diabetology 2021 20:178

   Content type: Original investigation Published on: 4 September 2021

   • View Full Text
   • View PDF

5. SGLT-2-inhibition with dapagliflozin reduces tissue sodium content: a randomised controlled trial

   Sodium tissue content by ²³Na magnetic resonance imaging (Na-MRI) has been validated in experimental and human studies. SGLT-2 inhibition blocks the reabsorption of glucose and of sodium in the proximal tubular c...

   Authors: M. V. Karg, A. Bosch, D. Kannenkeril, K. Striepe, C. Ott, M. P. Schneider, F. Boemke-Zelch, P. Linz, A. M. Nagel, J. Titze, M. Uder and R. E. Schmieder

   Citation: Cardiovascular Diabetology 2018 17:5

   Content type: Original investigation Published on: 4 January 2018

   • View Full Text
   • View PDF